Cytek Biosciences Net Income Over Time
| CTKB Stock | USD 4.47 0.03 0.67% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cytek Biosciences Performance and Cytek Biosciences Correlation. Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. Projected growth potential of Cytek fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cytek Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.735 | Earnings Share (0.11) | Revenue Per Share | Quarterly Revenue Growth 0.015 | Return On Assets |
Investors evaluate Cytek Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cytek Biosciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Cytek Biosciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Cytek Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cytek Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cytek Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Cytek Biosciences and related stocks such as Varex Imaging Corp, Avanos Medical, and Standard Biotools Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VREX | 109.6 M | 109.6 M | 109.6 M | 110.1 M | 80 M | 68.5 M | 51.6 M | 27.5 M | 15.5 M | (57.9 M) | 17.4 M | 30.3 M | 48.2 M | (47.7 M) | (69.9 M) | (62.9 M) | (59.8 M) |
| AVNS | 142.4 M | 142.4 M | 152.6 M | 154.6 M | 27.1 M | (426.3 M) | 39.8 M | 79.3 M | 57.5 M | (45.9 M) | (27.2 M) | 6.3 M | 50.5 M | (61.8 M) | (392.1 M) | (352.9 M) | (335.2 M) |
| LAB | (23.6 M) | (22.5 M) | (19 M) | (15.8 M) | (52.8 M) | (53.3 M) | (76 M) | (60.5 M) | (59 M) | (64.8 M) | (53 M) | (59.2 M) | (190.1 M) | (74.7 M) | (138.9 M) | (125 M) | (118.7 M) |
| CLPT | (9.5 M) | (8.3 M) | (5.7 M) | (7.1 M) | (4.5 M) | (8.4 M) | (8.1 M) | (7.2 M) | (6.2 M) | (5.5 M) | (6.8 M) | (14.4 M) | (16.4 M) | (22.1 M) | (18.9 M) | (17 M) | (16.2 M) |
| TMCI | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (3.7 M) | (20.6 M) | (42.8 M) | (49.5 M) | (55.7 M) | (50.2 M) | (47.7 M) |
| CBLL | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (37.2 M) | (29.5 M) | (40.5 M) | (36.4 M) | (38.2 M) |
| KIDS | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (7.9 M) | (6.6 M) | (8.9 M) | (12 M) | (13.7 M) | (32.9 M) | (16.3 M) | 1.3 M | (21 M) | (37.8 M) | (34 M) | (32.3 M) |
| ORGO | (2.9 M) | (25.2 K) | (25.2 K) | (25.2 K) | (25.2 K) | (25.2 K) | (208.7 K) | (2.1 M) | (64.8 M) | (38.7 M) | 17.2 M | 94.2 M | 15.5 M | 4.9 M | 861 K | 990.1 K | 940.6 K |
| ANGO | 343 K | (5.2 M) | (1.2 M) | 2.3 M | (3.4 M) | (43.6 M) | (7.1 M) | 16.3 M | 61.3 M | (166.8 M) | (31.5 M) | (26.5 M) | (52.4 M) | (184.3 M) | (34 M) | (30.6 M) | (29.1 M) |
Cytek Biosciences and related stocks such as Varex Imaging Corp, Avanos Medical, and Standard Biotools Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Cytek Biosciences financial statement analysis. It represents the amount of money remaining after all of Cytek Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Cytek Biosciences | CTKB |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 47215 Lakeview Boulevard, |
| Exchange | NASDAQ Exchange |
USD 4.47
Check out Cytek Biosciences Performance and Cytek Biosciences Correlation. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Cytek Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.